Meloxicam Dog Oral Suspension

SHAKE WELL BEFORE USE.

Wagg & Purr® Meloxicam Dog Oral Suspension should be administered mixed with food. On the first day of treatment a single dose of 0.2 mg/kg bodyweight should be given. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg/kg bodyweight. Particular care should be given with regard to the accuracy of dosing. Wagg & Purr® Meloxicam Dog Oral Suspension is administered by use of a graduated measuring syringe (0.5 mL increments) which is provided in the package. The syringe fits onto the bottle and has a kg-bodyweight scale designed for the maintenance dose (i.e. 0.1 mg/kg bodyweight). Thus, twice the volume should be administered on the first day as the initial dose. 

Initial Dose:

0.2 mg/kg bodyweight

2 maintenance dosage volumes

Maintenance Dose:

0.1 mg/kg bodyweight

1 maintenance dosage volume

For longer term treatment, once clinical response has been observed (after ≥ 4 days), the dose of Wagg & Purr® Meloxicam Dog Oral Suspension can be adjusted to the lowest effective individual dose, reflecting that the degree of pain and inflammation associated with chronic musculoskeletal disorders may vary over time. Should longer term treatment be contemplated, the prescribing veterinarian should observe current best practice including, but not limited to, regular monitoring of relevant clinical and biochemical parameters. If no improvement is noticeable after 10 days of treatment, please consult a veterinary surgeon.

Meloxicam 1.5 mg/mL

Wagg & Purr® Meloxicam Dog Oral Suspension is a non-steroidal anti-inflammatory drug (NSAID) for use in dogs. It is indicated for the alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders such as disco-spondylosis, arthropathy and soft tissue injuries.

This product is contraindicated for use in pregnant or lactating bitches. The use of the product is contraindicated in animals suffering from cardiac, hepatic or clinical renal disease. This product is also contraindicated where there is the possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of a haemorrhagic disorder or individual hypersensitivity to the product. Wagg & Purr® Meloxicam Dog Oral Suspension should not be administered concurrently with steroidal or other non-steroidal anti-inflammatory drugs, amino-glycoside antibiotics or anti-coagulant agents. Pre-treatment with anti-inflammatory drugs may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement with Wagg & Purr® Meloxicam Dog Oral Suspension. The treatment-free period, however, should take into account the pharmacokinetic properties of the drugs used previously